Clinical Trial Update: Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of olaparib and AZD6738 in IDH1/IDH2-mutant tumors, including refractory cholangiocarcinoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• AZD6738 (ceralasertib)
• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Solid Neoplasm, Refractory Cholangiocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-08